AR062603A1 - Derivados del acido indol-2-carboxilico, composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la modulacion del receptor ppargamma. - Google Patents
Derivados del acido indol-2-carboxilico, composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la modulacion del receptor ppargamma.Info
- Publication number
- AR062603A1 AR062603A1 ARP070103857A ARP070103857A AR062603A1 AR 062603 A1 AR062603 A1 AR 062603A1 AR P070103857 A ARP070103857 A AR P070103857A AR P070103857 A ARP070103857 A AR P070103857A AR 062603 A1 AR062603 A1 AR 062603A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- alkyl
- heterocyclyl
- aryl
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/22—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Derivados de indol que son moduladores de PPARalfa, composiciones farmacéuticas que los contienen, y a su uso en medicina para el tratamiento de enfermedades mediadas por PPARalfa Reivindicacion 1: Un compuesto de la formula (1) o una sal o solvato del mismo, en donde: R1 es -O-Ph-alquilo de 1 a 6 átomos de carbono, -NH-Ph-alquilo de 1 a 6 átomos de carbono, -CH2-Ph-halo-alquilo de 1 a 6 átomos de carbono, arilo o heterociclilo, en donde este arilo o heterociclilo está opcionalmente mono- sustituido con R7; R2 es halo-alquilo de 1 a 6 átomos de carbono, Ra-Rb-Rc, heterociclilo o arilo, en donde el arilo está opcionalmente sustituido con R8 y el heterociclilo está opcionalmente sustituido con R9; R3 es H, halo-alquilo de 1 a 6 átomos de carbono, o Ra-Rb-Rc; Ra es -O-; Rb es un enlace alquileno de 1 a 6 átomos de carbono, o -C(O)-; Rc es H, alquilo de 1 a 6 átomos de carbono, arilo, cicloalquilo de 3 a 6 átomos de carbono, alcoxilo de 1 a 6 átomos de carbono, -NR5R6, - O(CH2)2OCH3, o heterociclilo opcionalmente sustituido con 0=, o alquilo de 1 a 6 átomos de carbono; en donde : cuando Rb es un enlace, Rc es H o alquilo de 1 a 6 átomos de carbono; R4 y R5 son cada uno independientemente H o alquilo de 1 a 6 átomos de carbono; en donde cuando R3 y R4 son ambos H, R2 es arilo opcionalmente sustituido o heterociclilo opcionalmente sustituido; R6 es alquilo de 1 a 6 átomos de carbono, o tienil-alquileno de 1 a 6 átomos de carbono; R7 es alquilo de 1 a 6 átomos de carbono, -C(O)CH3, alcoxilo de 1 a 6 átomos de carbono, o halo-alquilo de 1 a 6 átomos de carbono; R8 es -OH, -CO2H, -O-alquilleno de 1 a 6 átomos de carbono-fenilo, alcoxilo de 1 a 6 átomos de carbono, -S-alquilo de 1 a 6 átomos de carbono, - S(O)2- alquilo de 1 a 6 átomos de carbono, -C(O)NR5R6, u -OC(CH3)2CO2H; y R9 es -C(O)CH3, -C(O)O-alquilo de 1 a 6 átomos de carbono, -C(O)O(CH2)2OCH3, -C(O)NH2, S-(O)2-alquilo de 1 a 6 átomos de carbono, -S(O)2NH2, o -S(O)2NC(O)o-alquilo de 1 a 6 átomos de carbono.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82412006P | 2006-08-31 | 2006-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR062603A1 true AR062603A1 (es) | 2008-11-19 |
Family
ID=38830380
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070103857A AR062603A1 (es) | 2006-08-31 | 2007-08-30 | Derivados del acido indol-2-carboxilico, composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la modulacion del receptor ppargamma. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20100240642A1 (es) |
EP (1) | EP2081894A1 (es) |
JP (1) | JP2010502648A (es) |
KR (1) | KR20090074179A (es) |
CN (1) | CN101563322A (es) |
AR (1) | AR062603A1 (es) |
AU (1) | AU2007289108A1 (es) |
BR (1) | BRPI0716250A2 (es) |
CA (1) | CA2662274A1 (es) |
CL (1) | CL2007002516A1 (es) |
EA (1) | EA200900254A1 (es) |
MX (1) | MX2009002283A (es) |
PE (1) | PE20080767A1 (es) |
TW (1) | TW200819447A (es) |
WO (1) | WO2008028118A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2550753T3 (es) * | 2007-04-16 | 2015-11-12 | Abbvie Inc. | Derivados de indol no sustituidos en la posición 7 como inhibidores de Mcl-1 |
US10973819B2 (en) | 2016-03-02 | 2021-04-13 | The University Of Chicago | Small molecules inhibitors of RAD51 |
AU2018294351B2 (en) | 2017-06-30 | 2022-12-22 | The Regents Of The University Of California | Compositions and methods for modulating hair growth |
WO2019199979A1 (en) | 2018-04-10 | 2019-10-17 | The General Hospital Corporation | Antibacterial compounds |
BR112022012149A2 (pt) * | 2019-12-20 | 2022-08-30 | The Regent Of The Univ Of California | Síntese de compostos para promover o crescimento do cabelo |
CN112479941B (zh) * | 2020-11-30 | 2023-01-13 | 沧州维智达美制药有限公司 | 一种2-取代-3-芳基卤苄衍生物的制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5684032A (en) * | 1994-12-13 | 1997-11-04 | Smithkline Beecham Corporation | Compounds |
WO2001030343A1 (en) * | 1999-10-22 | 2001-05-03 | Merck & Co., Inc. | Pharmaceuticals for treating obesity |
EP1341761A1 (en) * | 2000-10-10 | 2003-09-10 | Smithkline Beecham Corporation | SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-$g(g) BINDING AGENTS |
UA95788C2 (en) * | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
-
2007
- 2007-08-29 TW TW096132114A patent/TW200819447A/zh unknown
- 2007-08-29 PE PE2007001175A patent/PE20080767A1/es not_active Application Discontinuation
- 2007-08-29 CL CL200702516A patent/CL2007002516A1/es unknown
- 2007-08-30 AR ARP070103857A patent/AR062603A1/es not_active Application Discontinuation
- 2007-08-31 CA CA002662274A patent/CA2662274A1/en not_active Abandoned
- 2007-08-31 BR BRPI0716250-2A2A patent/BRPI0716250A2/pt not_active Application Discontinuation
- 2007-08-31 KR KR1020097006676A patent/KR20090074179A/ko not_active Application Discontinuation
- 2007-08-31 JP JP2009526929A patent/JP2010502648A/ja active Pending
- 2007-08-31 WO PCT/US2007/077365 patent/WO2008028118A1/en active Application Filing
- 2007-08-31 MX MX2009002283A patent/MX2009002283A/es not_active Application Discontinuation
- 2007-08-31 CN CNA2007800404569A patent/CN101563322A/zh active Pending
- 2007-08-31 US US12/438,024 patent/US20100240642A1/en not_active Abandoned
- 2007-08-31 EA EA200900254A patent/EA200900254A1/ru unknown
- 2007-08-31 AU AU2007289108A patent/AU2007289108A1/en not_active Abandoned
- 2007-08-31 EP EP07841701A patent/EP2081894A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CL2007002516A1 (es) | 2008-05-16 |
US20100240642A1 (en) | 2010-09-23 |
KR20090074179A (ko) | 2009-07-06 |
WO2008028118A1 (en) | 2008-03-06 |
CN101563322A (zh) | 2009-10-21 |
JP2010502648A (ja) | 2010-01-28 |
EP2081894A1 (en) | 2009-07-29 |
MX2009002283A (es) | 2009-03-20 |
PE20080767A1 (es) | 2008-08-08 |
CA2662274A1 (en) | 2008-03-06 |
AU2007289108A1 (en) | 2008-03-06 |
EA200900254A1 (ru) | 2009-08-28 |
TW200819447A (en) | 2008-05-01 |
BRPI0716250A2 (pt) | 2013-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR062603A1 (es) | Derivados del acido indol-2-carboxilico, composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la modulacion del receptor ppargamma. | |
AR057869A1 (es) | Compuesto cuaternario de (alfa)-aminocarboxiamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para preparar dicho compuesto | |
AR067051A1 (es) | Indazoles sustituidos, su preparacion y su utilizacion terapeutica | |
AR047890A1 (es) | Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3 | |
AR127309A2 (es) | Derivados de piridazinona | |
BRPI0608732A2 (pt) | composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto | |
AR061101A1 (es) | Compuesto de fenil-triazolil- metoxi- arilo, su uso para la manufactura de un medicamento y composicion farmaceutica que lo comprende | |
AR060237A1 (es) | Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende. | |
DE602006006850D1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
AR066882A1 (es) | Derivados de oxadiazol, una composicion farmaceutica que los comprende y su uso en la preparacion de medicamentos para el tratamiento de trastornos asociados con la disfuncion del glutamato. | |
AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
AR065844A1 (es) | Derivados de 8-(heteroarilmetoxi)quinolina, moduladores selectivos de receptores de bradiquinina (bk) b2, composiciones farmaceuticas que los contienen y usos en terapia. | |
AR082994A1 (es) | Derivados de pirazina como bloqueadores del canal epitelial de sodio | |
AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
CR10250A (es) | Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g | |
AR078884A1 (es) | Antagonistas del receptor crth2 basados en indol | |
AR053710A1 (es) | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos | |
AR062360A1 (es) | Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa | |
BRPI0607600A2 (pt) | derivados de 4-oxoquinazolin-3-il-benzamida para o tratamento de doenças relacionadas com citocina | |
PE20091425A1 (es) | Derivados de aminotiazol | |
AR111281A1 (es) | Compuestos de pirimidinil-piridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
BR0308146A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
ATE420859T1 (de) | Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |